Litigation Details for GALDERMA LABORATORIES, L.P. v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2024)

GALDERMA LABORATORIES, L.P. v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2024)

Docket		Date Filed	2024-01-11
Court	District Court, D. New Jersey	Date Terminated	2024-03-27
Cause	35:271 Patent Infringement	Assigned To	Michael Andre Shipp
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Parties	TEVA PHARMACEUTICALS, INC.
Patents	9,084,778; 9,498,465
Link to Docket	External link to docket

Details for GALDERMA LABORATORIES, L.P. v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-01-11				External link to document

Litigation summary and analysis for: GALDERMA LABORATORIES, L.P. v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2024)

Last updated: July 20, 2026

GALDERMA Laboratories v. Teva (3:24-cv-00197) Litigation Summary: What Patents Are Being Asserted, What the Procedural Posture Indicates, and What Generic Launch Risks Exist

Executive summary: The case GALDERMA Laboratories, L.P. v. Teva Pharmaceuticals, Inc., No. 3:24-cv-00197 (D.N.J.) is a Hatch-Waxman patent infringement dispute filed by Galderma against Teva. The docket number indicates a 2024 filing, and the matter fits a pattern where Galderma asserts Orange Book-listed patents covering a branded dermatology product and Teva challenges infringement based on non-infringement, invalidity, or both. The key business question for risk and timing is whether Galderma’s asserted claims survive early dispositive motion practice (Rule 12/summary judgment) and whether any PIV/settlement triggers delay of a Teva ANDA-based launch.

What this analysis covers: a litigation-only view focused on case posture, typical Hatch-Waxman dispute structure, likely patent-scope axes (formulation, method-of-use, and/or manufacturing), and generic launch risk mechanics tied to statutory exclusivity and court outcomes.

---

What patents are being asserted in GALDERMA v. TEVA Pharmaceuticals 3:24-cv-00197?

Answer (featured snippet): A complete and accurate list of asserted patent numbers, claim ranges, and asserted theory of infringement cannot be produced from the information provided (only the case caption and docket number).

Why asserted-patent identification drives case impact

For Hatch-Waxman cases, the market and litigation risk turn on:

• whether the asserted patents cover drug substance, specific formulation/excipients, delivery system (eg, topical vehicle or device-like features), use regimen, or manufacturing controls
• whether Galderma’s suit targets Orange Book-listed patents for the relevant NDA/label
• whether the asserted claims are method-of-use versus composition claims, which changes Teva’s potential non-infringement pathways

Litigation structure that typically appears in Galderma topical cases

Galderma’s dermatology portfolios frequently involve patents that fall into one or more of these technical buckets:

• formulation patents (stability, particle size, surfactant/solubilizer choices, viscosity, rheology)
• method-of-use patents (patient selection or specific dosing cadence)
• process/manufacturing patents (mixing order, temperature windows, milling, sterilization/handling)

In infringement disputes, these map directly to claim charts and technical expert workups, and they determine whether Teva’s ANDA at-issue product can be designed around by changing formulation or process.

---

What is the procedural posture in case 3:24-cv-00197 and what does it mean for timing?

Answer (featured snippet): With only the docket number provided, the exact procedural posture (complaint served status, answer, Rule 12 disposition, Markman schedule, discovery milestones, dispositive motion dates, trial setting, and claim construction outcomes) cannot be stated accurately.

Typical D.N.J. Hatch-Waxman timeline checkpoints to track

For investment, licensing, and litigation strategy, the most decision-relevant procedural events are:

1. Complaint + infringement contentions (asserted claims and “who infringes what”)
2. Answer + invalidity/non-infringement positions (the defenses Teva is committing to)
3. E.D.Tex/Markman equivalent in the district for claim construction scheduling
4. Summary judgment on non-infringement/invalidity (often early in fast-moving ANDA cases)
5. Trial or settlement if claim construction narrows the dispute

How posture translates to launch risk

• If the case reaches claim construction and the court narrows Galderma’s claim scope, Teva can gain leverage for non-infringement design-around.
• If Galderma survives dispositive motions, Teva’s probability-weighted launch date shifts later, and settlement pressure increases.
• If the matter settles early with an agreed “entry-for-forbearance” schedule, launch dates become contract-driven rather than court-driven.

---

What happens to the Teva ANDA entry date if Galderma wins in 3:24-cv-00197?

Answer (featured snippet): In Hatch-Waxman, a win typically results in an injunction or a finding of infringement that delays ANDA approval/entry to the extent required by the specific ruling.

Injunction mechanics that control real-world entry

Even when a court finds infringement, the practical entry outcome can depend on:

• whether asserted claims are held infringed and not invalid
• whether there is a stay pending appeal
• whether any remaining non-infringing design-around remains feasible
• whether the court’s scope is claim-specific

Revenue and business impact for a branded dermatology product

For a branded product, litigation outcomes can impact:

• generic entry timing (and thus erosion in 180-day or follow-on generic windows)
• negotiated settlements (which often include fixed-forbearance and sometimes market-share terms)
• label carve-outs if the brand’s method-of-use claims are narrowed

---

What generic entry risks exist for Teva under Hatch-Waxman in this dispute?

Answer (featured snippet): Teva’s entry risk depends on whether the at-issue ANDA is blocked by a live patent that the court enforces, and whether Teva can avoid infringement by changing the ANDA product or its intended use.

The three main risk vectors

1. Patent validity risk
   If Galderma’s patents survive invalidity arguments under §§ 101/102/103/112, Teva’s options shrink.
2. Infringement risk
   If claim construction favors Galderma and Teva’s product matches the construed elements, Teva’s non-infringement defense weakens.
3. Regulatory risk
   Even if patent claims are narrowed, FDA approval may still proceed on a separate schedule unless a statutory stay or court order blocks approval.

---

Is there a Paragraph IV certification or a settlement agreement in GALDERMA v. TEVA (3:24-cv-00197)?

Answer (featured snippet): Whether the Teva ANDA includes a Paragraph IV certification and whether the case reached settlement cannot be confirmed from the provided information.

How to interpret Paragraph IV in high-stakes timing

In Hatch-Waxman, Paragraph IV certification usually triggers:

• a 30-month stay (if the brand suit is timely and the statutory conditions are met)
• leverage for both sides to negotiate settlement

A settlement, when it exists, typically sets:

• an earlier/later forbearance end date
• sometimes a license to certain patents
• often covenants not to sue through a defined window

---

What is the Orange Book status of the patents at issue in 3:24-cv-00197?

Answer (featured snippet): Orange Book listing status, including listed patent numbers and expiration dates, cannot be determined from the provided information.

Why Orange Book status matters

For business decisions, Orange Book listing:

• determines which patents can be asserted in an ANDA-based Hatch-Waxman suit
• controls statutory stay and likely time-to-launch scenarios
• anchors claim scope, since only listed patents can be tied to the specific ANDA certification

---

How strong is the patent estate for Galderma in this dispute, based on litigation posture alone?

Answer (featured snippet): Strength cannot be quantified without the asserted patents, claim construction results, and the outcome of dispositive motions.

Litigation indicators typically used to gauge strength

When patent identity is known, strength is inferred from:

• early dismissals (Rule 12)
• the court’s claim construction
• expert reports and summary judgment records
• validity rulings tied to prior art and written description/enablement

With only the case identifier, none of those can be tied to factual outcomes.

---

How does GALDERMA’s litigation against TEVA compare with other Galderma Hatch-Waxman suits?

Answer (featured snippet): A comparative analysis across Galderma’s other Hatch-Waxman suits requires asserted-portfolio identification for this specific case and citation to other dockets; such data is not present.

What a meaningful comparison would cover

• frequency of formulation vs method-of-use claims
• whether Galderma targets topical formulation design-around more often than systemic dosage forms
• whether courts in similar cases have tended to uphold or narrow Galderma’s claim scope

---

Key litigation decisions that usually decide the outcome in D.N.J. ANDA patent suits

Answer (featured snippet): In Hatch-Waxman cases, the most outcome-determinative steps are claim construction and dispositive motion rulings; the specific steps and dates for this docket cannot be stated without docket entries.

Common decision points

• Markman: whether construed terms read broadly enough to cover the ANDA product
• Summary judgment: whether the court finds no infringement or invalidity as a matter of law
• Injunction/relief: whether the court issues constraints preventing entry

---

Key Takeaways

• The docket 3:24-cv-00197 is a Hatch-Waxman patent infringement dispute, and its business relevance is driven by whether Galderma’s asserted Orange Book-linked claims are upheld.
• A patent-by-patent view (numbers, claims asserted, claim construction outcomes, and validity rulings) is required for actionable launch-timing and settlement risk analysis.
• With only the case caption and docket number, the litigation outcome cannot be quantified, and the asserted patent estate cannot be mapped to expiration timelines or generic entry calendars.

---

FAQs

1. What does a Hatch-Waxman case number like 3:24-cv-00197 signal about timing risk?
   It signals a filed brand vs. ANDA litigation in 2024, where statutory stays and court outcomes can delay entry.

2. How do method-of-use vs. formulation patents change the design-around options for Teva?
   Method-of-use claims can often be avoided by changing label intent/use, while formulation claims can force technical redesign of the ANDA product.

3. What events in a district court docket most strongly predict generic launch?
   Claim construction decisions, summary judgment rulings, and any settlement orders that define forbearance.

4. How does Paragraph IV certification typically affect entry dates?
   It can trigger a 30-month statutory stay if the brand suit is timely and properly brought.

5. What court findings most often drive appeal and settlement leverage?
   Validity and claim construction determinations that narrow infringement exposure typically drive settlement economics.

---

References (APA)

No sources were cited because the request did not include docket documents, asserted patent identifiers, Orange Book details, or any outcome records for GALDERMA Laboratories, L.P. v. Teva Pharmaceuticals, Inc., No. 3:24-cv-00197.